An observational study in Severe Asthma, sponsored by AstraZeneca. Completed at 15 sites in Russia. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 96th largest by enrollment of the 110 observational ones that give a count, is one of 26 that started in 2024, is one of 111 observational ones, and was the 327th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 26 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is below the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ELBRUS is a 12-month (52-week), multi-centre, prospective, non-comparative and non-interventional (observational), post-reimbursement real-world evidence study that will assess patient-reported outcomes after tezepelumab treatment initiation in participants with severe asthma in Russia.
This is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who initiate tezepelumab for treatment of severe uncontrolled asthma. Participants of the study will be the patients eligible for tezepelumab treatment based on the assessment in accordance with the approved product Summary of Product Characteristics (SmPC) in Russia. The administration of tezepelumab will be independent of this study (i.e., a decision of tezepelumab initiation is based on the physician's choice and regulatory and clinical features, not on recruitment/participation in the study). Tezepelumab is indicated as an add-on maintenance treatment for severe asthma, therefore, patients will continue background asthma therapy throughout the study, irrespective of their decision to participate in this study or not.
Approximately 110 eligible participants of both sexes, aged 12 years or older will be treated with tezepelumab available in the market and according to the Russian reimbursement policies in approximately 20 sites. In eligible participants who agree to take part in the study, the enrolment date is defined as the date of informed consent or assent. After enrolment and evaluation of inclusion/exclusion criteria, study participants will commence tezepelumab treatment as per the physician's decision and following the local product SmPC. The index date is defined as the date when participants have received the first dose of tezepelumab. The enrolment period is the period between enrolment date and index date. Additionally, participants may be enrolled in this study up to 4 weeks after the first dose of tezepelumab, but no longer, to avoid responder bias.
Participants will be followed for a maximum period of 52 weeks after index date, irrespective of treatment discontinuation. Patient-reported outcomes - the primary endpoint (ACQ-5) and SNOT-22 will be retrospectively collected during enrolment for all patients (i.e. the most recent available values in the 52 weeks prior to index date), and prospectively collected at suggested visits at Weeks 4, 12, 24, and 52 following index date. For patients who initiate treatment after being enrolled into the study the baseline value may be collected prospectively after enrolment before start of treatment.
The baseline period is defined as the 52 weeks prior to the index date. Outcomes of interest, such as severe asthma exacerbations, medication use, and healthcare resource utilization, will be collected during enrolment retrospectively for the baseline period (52 weeks prior to the index date) and then prospectively at Weeks 4, 12, 24, and 52 following index date.
Overall expected duration of the study (from the first patient inclusion to the last patient last visit) is about 2 years or until 110 eligible patients are included to the study and data on these patients are collected, whichever occurs first.
As an observational, this study does not imply any intervention into a routine clinical practice, including choice of treatment modality or additional diagnostic methods.
Participants of both sexes, aged 12 years or older with severe uncontrolled asthma despite medium or high doses of ICS, who have commenced/will commence treatment with tezepelumab as determined by their routine clinical care.
The study population is planned to comprise approximately 110 participants in approximately 20 sites. Eligible patients will be enrolled consecutively at each site to minimize selection bias at each site
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
be eligible for enrolment into this study if all of the following criteria are met:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change in ACQ-5 score from baseline
time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation. Each question of the Asthma Control Questionnaire-5 is ranged on a 7-point scale from 0 (no impairment) to 6 (maximum impairment). The questions are equally weighted and the ACQ score is the mean of the all questions. The total score of ≥1.5 indicates a high probability that asthma is "poorly controlled", 0-0.75 - that asthma is "well controlled", and 0.75-1.5 is a "grey zone".
Time frame: 1 year
1. ACQ-5 score at different points of time
time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation. Each question of the Asthma Control Questionnaire-5 is ranged on a 7-point scale from 0 (no impairment) to 6 (maximum impairment). The questions are equally weighted and the ACQ score is the mean of the all questions. The total score of ≥1.5 indicates a high probability that asthma is "poorly controlled", 0-0.75 - that asthma is "well controlled", and 0.75-1.5 is a "grey zone".
Time frame: 1 year
2. Proportion of participants with well-controlled asthma
(ACQ-5 score ≤ 0.75) overall during the study and at different points of time \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]
Time frame: 1 year
3. Proportion of participants with ACQ-5 response
(reduction of ≥ 0.5 in score from baseline) overall during the study and at different points of time \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]
Time frame: 1 year
4. Median time to ACQ-5 response
(reduction of ≥ 0.5 in score from baseline), weeks \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following
Time frame: 1 year
8. Pre- and post-bronchodilator forced expiratory volume in 1 second
(FEV1) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]
Time frame: 2 years
9. Pre- and post-bronchodilator forced vital capacity
(FVC) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]
Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation
10. Pre-bronchodilator forced expiratory flow
(FEF) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]
Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation
11. Changes on pre- and post-bronchodilator FEV1 from baseline
time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation. Forced expiratory volume in 1 second (FEV1) response is defined as achievement of either a ≥ 5% or ≥ 100 mL improvement from baseline
Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation
12. Proportion of pre- and post-bronchodilator FEV1 responders
(defined as participants who achieved either a ≥ 5% or ≥ 100 mL improvement from baseline) overall during the study and at different points of time \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\];
Time frame: 1 year
13. FRC
Functional residual capacity (FRC) evaluated by spirometry and/or body plethysmography (if available) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]. Units of measurement: % predicted and L.
Time frame: 1 year
14. Annualised rate of severe asthma exacerbations
\[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: 2 years
15. Proportion of participants with reduced total number of severe asthma exacerbations at Week 52 following tezepelumab initiation compared with baseline
\[time points to measure: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]: a. Proportion of participants with any reduction in severe exacerbations number;
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
16. Change in annualised rate of severe asthma exacerbations from the baseline period to the follow-up period after tezepelumab initiation
\[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
17. Proportion of participants with 0, 1, 2, ≥3 severe asthma exacerbations
\[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
18. Cumulative days of severe asthma exacerbations
(calculated in participants who had severe asthma exacerbations at baseline) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
19. Proportion of participants with any SCS use
('systemic' means oral, parenteral CS) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
20. Proportion of participants with any reduction (≥ 25%, ≥ 50%, ≥ 75%, and 100% reduction) from baseline on cumulative SCS dose
(in prednisone equivalent dose) (to be calculated in participants with SCS use at baseline) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
21. Change in median SCS dose from baseline
(to be calculated in participants with SCS use at baseline) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
22. Proportion of participants with long-term (>30 consecutive days) SCS use
(to be calculated in participants with SCS use at baseline) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
23. Number (proportion) of participants with asthma-related healthcare resource utilisation
(by each type) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
24. Annualised rates of asthma-related hospitalisation, emergency calls (or emergency department visits), and unscheduled out-patient visits to a physician
\[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\];
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
25. Annualised rates of asthma-related scheduled physician visits or healthcare calls for asthma
\[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
26. Median overall duration (days) of asthma-related hospitalisations
\[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\].
Time frame: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation
27. Mean and median duration (days) of treatment with tezepelumab
to be calculated in all enrolled participants
Time frame: Week 52
28. Median time (days) to tezepelumab discontinuation
to be calculated in participants who discontinued tezepelumab earlier than Week 52 by any reason
Time frame: Week 52
29. Proportion of participants discontinued tezepelumab and switched to other biologic drug for asthma treatment and reason(s)
Time frame: Week 52
8.2 Changes on pre- and post-bronchodilator FVC from baseline
Forced Vital Capacity (FVC) (L): both pre-bronchodilator and post-bronchodilator should be recorded. time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation
Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation
8.3 Changes on pre-bronchodilator FEF from baseline
Pre-bronchodilator forced expiratory flow (FEF) 25-75 - the mean speed of flow during forced expiration of from 25% to 75% of the FVC. Measured in L/sec. time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation
Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation
12.b Proportion of participants with reduced total number of severe asthma exacerbations at Week 52 following tezepelumab initiation compared with baseline
\[time points to measure: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]: Proportion of participants with at least 50% reduction in severe exacerbations number;
Time frame: up to 2 years
12.c Proportion of participants with reduced total number of severe asthma exacerbations at Week 52 following tezepelumab initiation compared with baseline
\[time points to measure: baseline during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]: c. Proportion of participants who completed 52 weeks of tezepelumab treatment without any severe asthma exacerbation
Time frame: 2 years
10.2 RLV
Residual lung volume (RLV) evaluated by spirometry and/or body plethysmography (if available) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]. Units of measurement: % predicted and L.
Time frame: 1 year
10.3 TLC
Total lung capacity (TLC) evaluated by spirometry and/or body plethysmography (if available) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\]. Units of measurement: % predicted and L.
Time frame: 1 year
5. SNOT-22 questionnaire score
5\. SNOT-22 questionnaire score in patients with comorbid chronic rhinosinusitis with nasal polyps (rhinosinusitis polyposis) at different points of time
Time frame: baseline and at Weeks 4, 12, 24, and 52 following tezepelumab initiation
6. Proportion of participants with clinically meaningful improvement
Proportion of participants with clinically meaningful improvement (reduction in SNOT-22 score by ≥ 8.9) overall during the study and at different points of time
Time frame: baseline and at Weeks 4, 12, 24, and 52 following tezepelumab initiation
7. Median time to SNOT-22 response
Median time to SNOT-22 response (reduction of ≥8.9 in score from baseline), weeks \[time points to measure
Time frame: baseline and at Weeks 4, 12, 24, and 52 following tezepelumab initiation
1. Median time from index date to lung function response by FEV1
(FEV1 response is defined as achievement of either a ≥ 5% or ≥ 100 mL improvement from baseline) \[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\]
Time frame: 1 year
2. Proportion of participants with sustained (12 weeks or longer) response by FEV1
\[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\]
Time frame: 1 year
3. Median time from index date to spirometry and/or body plethysmography response
(spirometry and/or body plethysmography response is defined as achievement of a ≥ 5% improvement from baseline) \[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\];
Time frame: 1 year
4. Proportion of participants with sustained (12 weeks or longer) spirometry and/or body plethysmography response
\[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\]
Time frame: 1 year
5. Proportion of participants with medications for asthma treatment by drug class
\[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: 2 years
6. Cumulative dose of ICS by each ICS medication
(ICS may be contained in a single-component product and a combination product, e.g., ICS/LABA) \[time points to measure: during 52 weeks before tezepelumab initiation and up to 52 weeks following tezepelumab initiation\]
Time frame: 2 years
7. Medication possession ratio (MPR)
total days' supply of a medication in a particular time period, divided by the number of days in the time period
Time frame: Week 52
8. A patient's body weight (kg) measured in participants with elevated BMI at enrolment
(≥25 mg/m2) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\];
Time frame: 1 year
9. Change in body weight from baseline calculated in participants with elevated BMI at enrolment
(≥25 mg/m2) \[time points to measure: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation\].
Time frame: 1 year
10. Number and proportion of participants who achieved asthma clinical remission at Week 52
Time frame: Week 52
1.2 Median duration of lung function response by FEV1 from index date
time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation
Time frame: 1 year
3.2 Median duration of spirometry and/or body plethysmography response from index date (if available)
(spirometry and/or body plethysmography response is defined as achievement of a ≥ 5% improvement from baseline) \[time points to measure: baseline and at Weeks 12, 24 and 52 following tezepelumab initiation\];
Time frame: 1 year
Number and proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
Number and proportion of patients with chronic rhinosinusitis with nasal polyps (CRSwNP); * Number and proportion of patients with chronic rhinosinusitis without nasal polyps; * Number and proportion of patients with CRSwNP with different levels of eosinophils blood count: * \<150 cells/μl; * ≥150 cells/μl; * ≥300 cells/μl.
Time frame: baseline and at Weeks 4, 12, 24 and 52 following tezepelumab initiation
Number and proportion of patients with CRSwNP and presence of biologic therapy prior to tezepelumab initiationor
Number and proportion of patients with CRSwNP and presence of biologic therapy prior to tezepelumab initiationor
Time frame: 1 year
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Sep 2024 to primary completion in Oct 2026, 25 months.
Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's 25 months is close to that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Sep 2026 → Oct 2026 and completion Sep 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.